IGM BIOSCIENCES INC (IGMS)

Company Profile

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 198 full-time employees. The company went IPO on 2019-09-18. The firm is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. The company is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Company Info

IGM BIOSCIENCES INC

325 E Middlefield Rd

Mountain View CALIFORNIA 94043

P: 16509657873

CEO: Fred Schwarzer

Employees: 204

Website: https://igmbio.com/